DNAprint Genomics (DNAG)

[ann441j]

8/22/06 DNAP News Release:
(A re-read)

DNAPrint alliance targets ovarian cancer treatments
Tampa Bay Business Journal - August 22, 2006

DNAPrint Genomics Inc. has a strategic alliance with a Spanish firm to provide DNA sampling for ongoing research into theranostic (drug/test combinations) test and drug treatments for ovarian cancer.

Under the terms of the agreement, business units in Spain and in the United States of NeoCodex Inc. will gather DNA samples that will be tested by DNAPrint Genomics for research into the effectiveness of certain treatments for ovarian cancer. Specifically, it will involve combined treatments of Taxotere, Taxol, Carboplatin and Cisplatin.

No financial terms were disclosed.

NeoCodex SL is based in Sevilla, Spain and is a biomedical and genomic research provider. It is focused on understanding the molecular and genetic basis of human disease, and on employing novel methodologies for the continued improvement of current genetic analysis techniques, a release said.

DNAPrint Genomics Inc. in Sarasota is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals Inc. is a subsidiary, and develops diagnostic tests and theranostic products using the proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology.

Ann